Skip to content

comparison of lasix with methyldopa in control of postpartum hypertention in treated preeclamptic patients by Mgso4

comparison of lasix with methyldopa in control of postpartum hypertention in treated preeclamptic patients by Mgso4

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180114038349N1
Enrollment
120
Registered
2018-05-24
Start date
2016-07-22
Completion date
Unknown
Last updated
2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe preeclampsia in postpartum patients. Severe pre-eclampsia

Interventions

Intervention 1: First intervention group: 250 mg methyl dopamine 250 mg every 8 hours manufactured by Zahravi Pharmaceutical Company for up to one week. Intervention 2: Second Intervention group: 40 m

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patient with preeclampsia. Patient has been treated by Mgso4 The patient's blood pressure is between 140/90 to 160/100.

Exclusion criteria

Exclusion criteria: Patient has gestational diabetes. Patient has heart disease. Patient has renal disease. Patient has allergic reaction to lasix. Patient has allergic reaction to methyldopa.

Design outcomes

Primary

MeasureTime frame
The measure of patient's Systolic blood pressure that should be between 140 to 160 mm Hg. Timepoint: Blood pressure measurement in the first 24 hours after the intervention and in the second 24 hours after the intervention, and then a week later. Method of measurement: Mercury barometric device.;The measure of patient's diastolic blood pressure that should be between 90 to 100 mm Hg. Timepoint: Blood pressure measurement in the first 24 hours after the intervention and in the second 24 hours after the intervention, and then a week later. Method of measurement: Mercury barometric device.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSetareh Siahmansoori

Iran University of Medical Sciences

siahmansoori.s@tak.iums.ac.ir+98 21 4452 4857

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 18, 2026